These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
149 related items for PubMed ID: 9184391
21. Ristocetin- and thrombin-induced platelet aggregation at physiological shear rates: differential roles for GPIb and GPIIb-IIIa receptor. Kasirer-Friede A, Frojmovic MM. Thromb Haemost; 1998 Sep; 80(3):428-36. PubMed ID: 9759623 [Abstract] [Full Text] [Related]
22. [Ristocetin induced platelet aggregation in children with nephrotic syndrome]. Taira K, Okajima C, Yamashita T, Kawahara S, Matsunaga T, Nakajima M, Kamitsuji H. Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):659-66. PubMed ID: 2214316 [Abstract] [Full Text] [Related]
27. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Casonato A, Steffan A, Pontara E, Zucchetto A, Rossi C, De Marco L, Girolami A. Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996 [Abstract] [Full Text] [Related]
28. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor. Cauwenberghs N, Schlammadinger A, Vauterin S, Cooper S, Descheemaeker G, Tornai I, Deckmyn H. Thromb Haemost; 2001 Apr; 85(4):679-85. PubMed ID: 11341505 [Abstract] [Full Text] [Related]
31. [Chronic peripheral arterial occlusive disease, platelet glycoproteins GPIIb-IIIa and GP Ib-IX, plasma von Willebrand factor and plasma fibrinogen concentrations in patients with type 2 diabetes mellitus]. Gosk-Bierska I, Adamiec R, Doskocz W, Ciosek W. Pol Arch Med Wewn; 2000 Apr; 103(3-4):139-45. PubMed ID: 11236240 [Abstract] [Full Text] [Related]
32. Platelet dysfunction in outpatients with left ventricular assist devices. Steinlechner B, Dworschak M, Birkenberg B, Duris M, Zeidler P, Fischer H, Milosevic L, Wieselthaler G, Wolner E, Quehenberger P, Jilma B. Ann Thorac Surg; 2009 Jan; 87(1):131-7. PubMed ID: 19101285 [Abstract] [Full Text] [Related]
34. Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino-terminal region flanking the A1 domain. Shibata M, Shima M, Fujimura Y, Takahashi Y, Nakai H, Sakurai Y, Asatani M, Nomura A, Take H, Giddings JC, Yoshioka A. Thromb Haemost; 1999 May; 81(5):793-8. PubMed ID: 10365755 [Abstract] [Full Text] [Related]
35. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, Regnier O, Legrand Y, Caen JP. Thromb Haemost; 1991 Dec 02; 66(6):633-7. PubMed ID: 1724577 [Abstract] [Full Text] [Related]
36. Ristocetin-mediated interaction of human von Willebrand factor with platelet glycoprotein lb evokes a transient calcium signal: observations with Fura-PE3. Milner EP, Zheng Q, Kermode JC. J Lab Clin Med; 1998 Jan 02; 131(1):49-62. PubMed ID: 9452127 [Abstract] [Full Text] [Related]
37. Neutralization of the local negative charge carried by glycoprotein (GP)-Ib in ristocetin-induced platelet agglutination. Tanoue K, Jung SM, Yamamoto N, Yamazaki H. Thromb Haemost; 1984 Feb 28; 51(1):79-83. PubMed ID: 6232731 [Abstract] [Full Text] [Related]
38. Plasma levels of von Willebrand factor and plasminogen activator in patients with arterial thromboembolism--with special reference to their correlation to the increased catabolism of both fibrinogen and platelets. Matsumoto M, Uchiyama T, Kobayashi N, Maekawa T. Nihon Ketsueki Gakkai Zasshi; 1989 Sep 28; 52(6):1105-14. PubMed ID: 2588960 [Abstract] [Full Text] [Related]